Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Nantahala to nominate 2 board seats

Portion of the proceeds received from warrants executed at $8.16/share

SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI^® (metoclopramide) nasal spray, announced today that it received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants.

Read more at globenewswire.com